M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Jabil has acquired contract development and manufacturing organisation (CDMO) Pharmaceutics International (Pii) to offer ...

Syngene is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), (OTCPK:AAPGV) which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering. In an SEC filing ...

At the proposed price, Ascentage Pharma Group International would command a fully diluted market value of $1.8 billion, noted the company, whose shares rose 13.7% to HK$44.00 following the ...

The past two years have been punishing for the biotech and pharma space. As Wall Street chased the artificial-intelligence boom, drugmakers were left behind, with pharma stocks trading at a ...

NEW DELHI: India is bracing for possible disruptions to its pharmaceutical industry - where the American market accounts for almost a third of exports - during Donald Trump’s presidency.

Shares of WuXi group companies jumped Monday after U.S. President-elect Trump promised to save TikTok and held a call with his counterpart in China, sparking tentative hopes that some areas of U.S ...

CSPC Pharmaceutical Group (CSPC) is a pharmaceutical company, which provides innovative, generic and bulk drugs. The company manufactures, research and markets medicines and pharmaceutical related ...